EBACU (European Biotech Acquisition) Price-to-Free-Cash-Flow : N/A (As of May. 16, 2025)

European Biotech Acquisition Price-to-Free-Cash-Flow Chart

Competitive Comparison of European Biotech Acquisition's Price-to-Free-Cash-Flow

For the Shell Companies subindustry, European Biotech Acquisition's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

European Biotech Acquisition's Price-to-Free-Cash-Flow Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, European Biotech Acquisition's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where European Biotech Acquisition's Price-to-Free-Cash-Flow falls into.

European Biotech Acquisition Price-to-Free-Cash-Flow Calculation

European Biotech Acquisition's Price-to-Free-Cash-Flow ratio for today is calculated as

European Biotech Acquisition's Share Price of today is $11.30.
European Biotech Acquisition's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

European Biotech Acquisition  (NAS:EBACU) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.

Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.

European Biotech Acquisition Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of European Biotech Acquisition's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

European Biotech Acquisition Business Description